Compare Humana Inc (HUM) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Quantumscape Corp — how do they compare? Humana Inc trades at $431.03 (market cap $46.49B), while Quantumscape Corp trades at $4.58 (market cap $2.82B). The key difference: Humana Inc is far larger — about 16.5× Quantumscape Corp's market cap, and Humana Inc pays a 0.91% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Quantumscape Corp for 37 Days on average.
| HUM | QS | |
|---|---|---|
Market Cap | $46.49B | $2.82B |
Volume | 2,567,704 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $18.44 |
52-Week Low | $163.67 | $4.52 |
Typical Hold Time | 51 Days | 37 Days |
Enterprise Value | $53.84B | $2.03B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
QuantumScape trades at $4.58, up 1.33% on the day but remains near 52-week lows. The stock shows bearish technical signals with negative profitability metrics and no revenue generation. Recent earnings showed mixed results with two beats and one miss, while cash flow remains heavily dependent on financing activities. The company continues developing solid-state battery technology with commercialization targeted for 2029.
Outlook remains challenging with significant execution risk and negative analyst sentiment. The consensus price target of $10.35 offers potential upside but requires successful commercialization. Key risks include delayed timelines, intense competition, and continued cash burn. Investment appeal is limited to speculative investors comfortable with high-risk, long-term technology development timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
